On approval of Co-payment Rules

Unofficial translation

Order of the Minister of Healthcare of the Republic of Kazakhstan dated July 16, 2021, No. ҚР ДСМ-61. Registered with the Ministry of Justice of the Republic of Kazakhstan on July 19, 2021, No. 23589.

Unofficial translation

Note!

The order was suspended until 31.12.2025 by Order of the Acting Minister of Health of the Republic of Kazakhstan dated 01.08.2023 № 143 (effective ten calendar days after the date of its first official publication).

Note!

The order was suspended until 31.12.2022 by the order of the Acting Minister of Health of the Republic of Kazakhstan dated 05.11.2021 № ҚР ДСМ-109 (effective from the moment of its first official publication).

In accordance with subparagraph 93) of Article 7 of the Code of the Republic of Kazakhstan 'On Public Health and the Healthcare System', **I HEREBY ORDER:"**

Footnote: The preamble is presented in the wording of the Order of the Acting Minister of Healthcare of the Republic of Kazakhstan dated 3 October 2025 № 104 (shall enter into force upon expiry of ten calendar days after the day of its first official publication).

1. To approve the attached co-payment rules.

2. To recognize as terminated the order of the Minister of Healthcare of the Republic of Kazakhstan dated December 31, 2019, № ҚР ДСМ-154 "On approval of the Rules for the implementation of co-payment for medicines and medical devices" (registered in the Register of State Registration of Normative Legal Acts under № 19814).

3. The Department of Pharmaceutical Policy of the Ministry of Healthcare of the Republic of Kazakhstan, in accordance with the procedure established by the legislation of the Republic of Kazakhstan, shall ensure:

1) state registration of this order with the Ministry of Justice of the Republic of Kazakhstan;

2) placement of this order on the Internet resource of the Ministry of Healthcare of the Republic of Kazakhstan after its official publication;

3) within ten working days after the state registration of this order with the Ministry of Justice of the Republic of Kazakhstan, submission to the Legal Department of the Ministry of Healthcare of the Republic of Kazakhstan of information on the implementation of the measures provided for in subparagraphs 1) and 2) of this paragraph.

4. To impose control over the execution of this order on the supervising Vice Minister of Healthcare of the Republic of Kazakhstan.

5. This order shall come into effect after the expiration of ten calendar days after the day of its first official publication.

Minister of Healthcare
of the Republic of Kazakhstan *A. Tsoi*

Annex
to the Order of the
Minister of Healthcare of the
Republic of Kazakhstan
dated July 16, 2021, № КР ДСМ -61

Rules for Co-Payment

Footnote: The Rules are presented in the wording of the Order of the Acting Minister of Healthcare of the Republic of Kazakhstan dated 3 October 2025 № 104 (shall be enforced upon the expiration of ten calendar days after the day of its first official publication).

Chapter 1. General provisions

1. These Rules for co-payment (hereinafter - the Rules) have been developed in accordance with subparagraph 93) of Article 7 of the Code of the Republic of Kazakhstan " On Public Health and the Healthcare System" and shall determine the procedure for making co-payments.

2. The following basic concepts are used in these Rules:

1) the information system for accounting for outpatient drug provision (hereinafter - ISDP) - an information system designated by the authorized body in the field of healthcare for automating the accounting of prescription issuance, product dispensation to providers of pharmaceutical services or services for the accounting and sale of medicines and medical devices within the guaranteed volume of free medical care (hereinafter - GVFMC) and/or in the system of compulsory social health insurance (hereinafter - CSHI);

2) the Social Health Insurance Fund (hereinafter – the Fund) – a non-profit organization that accumulates deductions and contributions, and also procures and pays for services of healthcare providers rendering medical care within the volumes and under the conditions stipulated by the contract for the purchase of medical services, and performs other functions defined by the laws of the Republic of Kazakhstan;

3) co-payment – the voluntary payment of the difference between the cost of medicines and/or medical devices and the established maximum reimbursement price for them within the framework of the Guaranteed Volume of Free Medical Care (GVFMC) and/or the Compulsory Social Health Insurance (CSHI) system at the outpatient level;

4) maximum reimbursement price for medicines and medical devices under the co-payment scheme – the selling price of medicines and/or medical devices, not exceeding

the maximum price for the international nonproprietary name of medicines and the technical characteristics of the medical device within the GVFMC and the CSHI system;

5) entities in the sphere of circulation of medicines and medical devices – individuals or legal entities engaged in pharmaceutical activities;

6) international nonproprietary name (INN) of a medicine – the name of a medicine recommended by the World Health Organization;

7) trade name of a medicine – the name under which a medicine is registered;

8) information system for co-payment of entities in the sphere of circulation of medicines and medical devices and/or a consortium (hereinafter – the ISC) – an information system (software product) used for automating the processes of outpatient drug provision involving co-payment, which is subject to mandatory testing and confirmation of compliance with the requirements of the legislation of the Republic of Kazakhstan in the field of information security prior to its implementation and operation;

9) consortium – a temporary, voluntary, equal union (association) based on an agreement on joint economic activity, in which legal entities pool certain resources and coordinate efforts to solve specific economic tasks;

10) trade name of a medical device – the name under which a medical device is registered ;

11) maximum price for the international nonproprietary name of a medicine or the technical characteristics of a medical purpose item, medical devices for in vitro diagnostics, manufactured in the territory of the Republic of Kazakhstan under long-term supply agreements concluded with the Single distributor, within the guaranteed volume of free medical care and/or in the system of compulsory social health insurance – the price for the international nonproprietary name of a medicine or the technical characteristics of a medical purpose item, medical devices for in vitro diagnostics, manufactured in the territory of the Republic of Kazakhstan under long-term supply agreements concluded with the Single distributor, registered in the Republic of Kazakhstan, above which procurement cannot be made within the guaranteed volume of free medical care and/or in the system of compulsory social health insurance;

12)"e-government" mobile application – a software product installed and launched on a cellular subscriber device, providing access to state services and services rendered in electronic form via cellular communication and the Internet.

Chapter 2. Procedure for making co-payments

3. Co-payment for medicines and/or medical devices shall be made during the free and/or subsidized outpatient provision of medicines and/or medical devices to specific categories of citizens of the Republic of Kazakhstan with certain diseases (conditions) within the framework of the Guaranteed Volume of Free Medical Care (GVFMC) and/or the Compulsory Social Health Insurance (CSHI) system.

4. Patients or their legal representatives, when receiving medicines and/or medical devices , shall be granted the right to choose one of the following methods:

1) free provision of medicines and/or medical devices through pharmacy points located in healthcare organizations providing primary health care and/or consultative-diagnostic care, as well as through mobile pharmacy points operating in rural settlements.

2) provision of medicines and/or medical devices using co-payment through entities in the sphere of circulation of medicines and medical devices that have a contract with the Fund.

Healthcare professionals, when prescribing in the Information System for Outpatient Drug Provision (ISDP), shall obtain the consent of the patient or their legal representative regarding the choice of the co-payment method.

5. After a healthcare worker prescribes a medication for outpatient drug provision, the patient or their legal representative is informed via:

the personal account in the "e-government" mobile application, and/or the mobile application of the Information System for Co-payment (ISC), and/or the ISC internet resource , which possess electronic prescription functionality and are integrated with the Information System for Outpatient Drug Provision (ISDP). The information provided includes the registered trade names of medicines and/or medical devices corresponding to the international non-proprietary name, pharmaceutical form, and dosage; the addresses of pharmacies participating in the co-payment scheme; and the availability of the required medicines and/or medical devices at those pharmacies, indicating their cost and the co-payment amount.

6. The provision of the medicine and/or medical device to the patient or their legal representative shall be carried out by international non-proprietary name, taking into account the pharmaceutical form and dosage, by scanning an electronic prescription (QR code). This code is presented via the "Social Wallet" service within the "e-government" mobile application and/or the mobile application/internet resource of the ISC, which possess electronic prescription functionality and are integrated with the ISDP.

7. The implementation of the co-payment shall be facilitated through the Information System for Co-payment (ISC), which notifies the patient or their legal representative of the possibility to receive medicines and/or medical devices in accordance with paragraph 5 of these Rules.

8. The ISC shall ensure:

1) transmission of information to the "e-government" mobile application and/or the ISC mobile application and/or the ISC internet resources, which have electronic prescription functionality and are integrated with the ISDP, regarding pharmacies participating in the co-payment scheme, the availability of medicines and/or medical devices therein, indicating their cost and the co-payment amount;

2) conclusion of a co-payment agreement;

3) generation, approval, or rejection of a consolidated register of fulfilled prescriptions by entities in the sphere of circulation of medicines and medical devices and/or a consortium, using the form provided in Appendix 1 to these Rules;

4) generation and approval of an act of payment for pharmaceutical services by entities in the sphere of circulation of medicines and medical devices and/or a consortium, using the form provided in Appendix 2 to these Rules;

5) automated transfer of data to the ISDP regarding the fulfilment of a prescription upon the actual issuance of the medicine and/or medical device to the patient, indicating the date of dispensation, the details of the cash register receipt confirming the fact of dispensation, and the status of the marking code of the dispensed medicine and/or medical device.

9. The consortium and/or entities in the sphere of circulation of medicines and medical devices shall submit an application to the Fund for the conclusion of a co-payment agreement.

10. Entities in the sphere of circulation of medicines and medical devices participating in the co-payment scheme must meet the following criteria:

1) possession of a pharmacy network comprising at least seventy (70) pharmacies located in no fewer than three (3) regions, cities of republican significance, and/or the capital;

2) possession of, or connection to, an Information System for Co-payment (ISC) that complies with the functions and requirements specified in paragraphs 8 and 12 of these Rules, ensuring the technical capability for every pharmacy within the entity's network to operate with this system.

11. A consortium must meet the following criteria:

1) the participants of the consortium shall collectively ensure the implementation of the co-payment through a pharmacy network comprising at least two hundred (200) pharmacies located in no fewer than five (5) regions, cities of republican significance, and/or the capital;

2) possession of, or connection to, an Information System for Co-payment (ISC) that complies with the functions and requirements specified in paragraphs 8 and 12 of these Rules, ensuring the technical capability for every pharmacy within the network of the entities in the sphere of circulation of medicines and medical devices to operate with this system;

3) existence of a concluded agreement on the establishment of the consortium, stipulating equal terms of reimbursement for each participant within the co-payment framework.

12. The Information System for Co-payment (ISC) shall be approved for use within the co-payment framework upon possession of a test act or protocol confirming compliance with information security requirements.

13. The Fund shall review the submitted application within a period not exceeding five (5) working days. If the criteria specified in paragraphs 10 and 11 of these Rules are met, the Fund shall conclude an agreement with the entity in the sphere of circulation of medicines and medical devices and/or the consortium, represented by one of the entities in the sphere of circulation of medicines and medical devices (hereinafter - the official representative of the consortium).

14. The official representative of the consortium shall be designated by the consortium participants based on the consortium establishment agreement.

The consortium establishment agreement shall specify:

1) name of the participant authorized to represent the consortium's interests in relations with the Fund;

2) the scope of authority of the official representative, including the right to sign the agreement with the Fund, and to submit the consolidated register and the payment act;

3) the procedure for making decisions regarding the replacement of the consortium's official representative;

4) the liability of the official representative to the other consortium participants for the accuracy of the information provided and the fulfilment of obligations under the co-payment agreement.

The Fund shall not interfere in the internal contractual relations of the consortium participants concerning the selection, replacement, or recall of the official representative, or the procedures for fund distribution and decision-making.

15. The form of the co-payment agreement shall be approved by the authorized body of the Fund, in accordance with civil legislation and executive legislation in the field of healthcare.

16. Entities in the sphere of circulation of medicines and medical devices and/or the official representative of the consortium shall not use the information collected in the course of implementing the co-payment scheme for any other commercial purposes not provided for by the co-payment.

17. The operator of the "e-government" mobile application shall provide the possibility of integration (data exchange) within the co-payment framework to entities in the sphere of circulation of medicines and medical devices and/or the official representative of the consortium with whom the Fund has concluded a co-payment agreement.

Chapter 3. Procedure for payment of pharmaceutical services within the Framework of co-payment

18. The Fund shall pay for pharmaceutical services within the co-payment framework to entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium for actually rendered pharmaceutical services, using budgetary funds and assets of the Fund based on a co-payment agreement.

19. The grounds for payment for pharmaceutical services to entities in the sphere of circulation of medicinal products and medical devices, and/or the official representative of the consortium shall be:

1) a consolidated register of fulfilled prescriptions by entities in the sphere of circulation of medicinal products and medical devices, and/or the consortium, in the form according to Appendix 1 to these Rules (hereinafter - the consolidated register);

2) a payment certificate for pharmaceutical services issued by entities in the sphere of circulation of medicinal products and medical devices, and/or the consortium, in the form according to Appendix 2 to these Rules (hereinafter referred - the payment certificate).

20. The reporting period for payment of pharmaceutical services within the co-payment framework is a calendar month. Payment for December of the current year shall be made in the next financial year.

By agreement between the Fund and the entity in the sphere of circulation of medicinal products and medical devices, and/or the official representative of the consortium, and subject to technical capabilities and financial resources, the duration of the reporting period may be set to less than a calendar month.

21. Entities in the sphere of circulation of medicinal products and medical devices, and/or the official representative of the consortium shall submit the consolidated register, generated in the ISC, as well as the payment certificate on paper and/or via the ISC.

22. The consolidated register shall be submitted by the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium to the Fund monthly, no later than the 25th (twenty-fifth) day of the month following the reporting period.

The consolidated register for payment of pharmaceutical services for December of the current year shall be submitted by the 25th (twenty-fifth) of January of the year following the reporting financial year.

23. The Fund shall review and approve the consolidated register within 10 (ten) business days from the date of its receipt.

24. After the Fund approves the consolidated register, the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium shall submit the payment certificate to the Fund.

25. Upon receipt of the payment certificate, the Fund shall review and sign it within 5 (five) business days.

26. The Fund shall make the payment to the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium within 5 (five) calendar days from the date of signing the payment certificate.

27. The Fund shall pay the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium for medicinal products at the maximum price for the international non-proprietary name, but not higher than the price for the brand name.

The patient shall not make an additional co-payment if the price of the brand-name medicinal product and/or medical device is lower than the maximum price established for the corresponding international non-proprietary name.

28. The payment deadline stipulated in paragraph 26 of these Rules shall be suspended in the event of untimely transfer of budgetary funds to the Fund.

29. The grounds for termination of the co-payment agreement shall be the violation and/or failure to comply with the conditions stipulated in clauses 10, 11, 12, 22, and 24 of these Rules, namely the untimely or improper submission of the consolidated register and the payment certificate, violation of the requirements for connecting to and operating the ISC, as well as information security requirements.

Termination of the agreement shall be carried out by sending a written notification to the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium.

The agreement shall be considered terminated from the moment the specified notification is received by the entities in the sphere of circulation of medicinal products and medical devices and/or the official representative of the consortium.

Appendix 1 to the Rules
for co-payment
Form

Consolidated register of fulfilled prescriptions by entities in the sphere of circulation of medicinal products and medical devices and/or the consortium

for the period _____ № _____ dated "" _____ 20

for the period from "" _____ 20 to "" _____ 20

under the Agreement for payment of pharmaceutical services within the co-payment framework

№ ____ dated "" _____ 20

Name and BIN of the supplier (entity in the sphere of circulation of medicinal products and medical devices and/or the official representative of

the consortium that concluded the co-payment agreement with JSC "Social Health Insurance Fund")

_____

Serial №	Name of the entity in the sphere of circulation of medicinal products and medical devices that actually supplied the prescription	BIN of the entity in the sphere of circulation of medicinal products and medical devices that actually supplied the prescription	Region	ICD-10 Code	Patient's IIN	Number and date of the supplied prescription	International non-proprietary name of the supplied medicinal product
1	2	3	4	5	6	7	8

continuation

Trade name of the supplied medicinal product (TN)	Dosage and release form	Unit of measurement	Maximum reimbursement price per unit of measurement, in tenge	Fiscal receipt number	Medicine labeling number (code)	Price reimbursement by the Fund, in tenge	Price paid by the patient, in tenge (co-payment amount)	Total amount, in tenge
9	10	11	12	13	14	15	16	17=15+16

The total cost of the pharmaceutical service within the co-payment framework was _____ tenge.

Submitted by:

Entity in the field of circulation of medicines and medical devices and/or official representative of the consortium _____

_____

Agreed by:

NJSC "Social Health Insurance Fund" _____

_____

*The trade name is indicated from the state register of medicines and medical devices

Appendix 2 to the Rules
for co-payment
Form

Payment certificate for pharmaceutical services by entities in the field of circulation of medicines and medical devices, and (or) a consortium

№ _____ dated "___" _____ 20 ___

for the period from "___" _____ 20 ___ to "___" _____ 20 ___

under the Agreement for payment of the cost of pharmaceutical services within the co-payment framework

№ ____ dated "___" _____ 20 ___

Serial №	Region	Name of the supplier (entity in the field of circulation of medicines and medical devices and (or) official representative of the consortium that has entered into a co-payment agreement with the NAO Social Health Insurance Fund)	Предъявлено к оплате Billed for Payment	
			Number of prescriptions supplied within the co-payment framework	Reimbursement amount by the Fund, in tenge
1	2	3	4	5
1				

2		Total amount of prescriptions supplied within the co-payment framework, tenge	

Submitted by:
Entity in the field of circulation of medicines and medical devices
and/or official representative of the consortium

_____

Agreed upon by:
NJSC "Social Health Insurance Fund"

_____